#gonorrhea

This video is about disclosing HIV status on dating apps.

Highlights from the research presented at the 9th International AIDS Society Conference on HIV Science in Paris.

Following a recent finding of a major drop in HIV diagnoses at the 56 Dean St. clinic, the decline in gonorrhea diagnoses is encouraging.

The vaccine may inform future research into a gonorrhea-specific vax.

The science behind Truvada as pre-exposure prophylaxis reveals an awesome tool that is apparently already helping shrink U.S. HIV rates.

With three identified cases, in Japan, France and Spain, proving untreatable, the World Health Organization has issued a call to action.

It is unclear how going on Truvada (tenofovir/emtricitabine) as pre-exposure prophylaxis (PrEP) may have affected these rates.

However, might post-exposure prophylaxis (PEP) against STIs impact resistance to antibiotics among infections like gonorrhea?

Noting past mistakes in testing protocol, researchers hope for new antibiotics and genetic screening that can guide treatment.

A modeling study suggests that HIV meds’ effects on the immune response may partially explain the recent rise in syphilis in gay and bi men.

Lab tests suggest that mouthwash combats the bacteria that cause the increasingly common sexually transmitted infection.

Syphilis cases spiked 333% since 2003, but a U.S. Senate bill wants to cut $5M from STD prevention.

Men who have sex with men (MSM) account for most new cases of gonorrhea and syphilis.

The CDC’s first state-by state breakdown of rates of the STI among men who have sex with men reveals a heavy burden in the South.

The last line of defense against the STI is weakening; however, an experimental treatment showed promise in a recent Phase II trial.

The World Health Organization has recommended updated treatment protocols to combat drug-resistant gonorrhea, chlamydia and syphilis.